

TO: Vermont Health Care Providers and Health Care Facilities
FROM: Dr. Mark Levine, Commissioner of Health

Updated guidance for administering COVID-19 therapies, Evusheld and Sotrovimab

BACKGROUND:

Emergency Use Authorizations (EUAs) for two monoclonal antibody therapies have recently been updated.

- As of February 24, 2022, the dosing for [Evusheld](#) has been updated:
 - The initial dosage of Evusheld is now 300 mg of tixagevimab and 300 mg cilgavimab administered as two consecutive intramuscular injections.
 - For patients who received a dose of Evusheld prior to February 24, 2022, providers should schedule these patients to receive additional doses (tixagevimab 150 mg and cilgavimab 150 mg).
- As of February 23, 2022, the duration of infusion and the timing of administration of [sotrovimab](#) has changed:
 - Administer sotrovimab 500 mg intravenously over 15 minutes for 50 mL infusion bag OR over 30 minutes for 100 mL infusion bag.
 - Sotrovimab should be given within seven days of symptom onset (previously 10 days).

REQUESTED ACTION:

Be familiar with the updated Emergency Use Authorizations for Evusheld and sotrovimab.

[Evusheld EUA](#)

[Sotrovimab EUA](#)

View a side-by-side comparison of all available COVID-19 outpatient therapies.

<https://aspr.hhs.gov/COVID-19/Therapeutics/Documents/side-by-side-overview.pdf>

For a list of updated sites, please use this tool to locate available therapeutics near you.

<https://covid-19-therapeutics-locator-dhhs.hub.arcgis.com/>

If you have any questions, please contact the HAN Coordinator at 802-859-5900 or

vthan@vermont.gov.

HAN Message Type Definitions

Health Alert: Conveys the highest level of importance; warrants immediate action or attention.

Health Advisory: Provides important information for a specific incident or situation may not require immediate action.

Health Update: Provides updated information regarding an incident or situation; unlikely to require immediate action.

Info Service Message: Provides general correspondence from VDH, which is not necessarily considered to be of an emergent nature.